This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Solid Tumours
and you are
over 20
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is the first clinical experience in Japan with GSK1120212, a novel MEK inhibitor. This study is designed to identify recommended doses and regimens in Japanese subjects for the future development of GSK1120212.

Provided treatments

  • Drug: GSK1120212
  • Drug: Gemcitabine

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01324258. The sponsor of the trial is GlaxoSmithKline and it is looking for 19 volunteers for the current phase.
Official trial title:
A Phase I Trial of GSK1120212 and GSK1120212 in Combination With Gemcitabine in Japanese Subjects With Solid Tumors